Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.
|Articles|December 4, 2015
Orphan Drug Market to Grow at Over 10% CAGR to 2019
December 04, 2015.
Advertisement
Research and Markets released its report Global Orphan Drugs Market 2015-2019, forecasting the market to grow at a CAGR of 10.05% over the period 2014-2019.
Research analysts noted emerging trends in the orphan drug market are a focus on biologics, shorter drug development timelines, and the challenges of enrollment. Conducting clinical trials in rare diseases with smaller number of patients available for clinical studies is around recruiting enough patients to generate significant comparative data.
Read the full
Advertisement
Related to this article
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
How the shifting tides in information consumption are resetting expectations for pharma in providing and delivering health education.
Pharma brands with all the right information are still invisible to AI — and why silence is the bigger risk than inaccuracy.
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
The advantages of synthetic advisory boards in stress-testing hypotheses and iterating across a greater scope of scenarios than live boards allow.
As leaders, we must evaluate solutions to fragmentation by asking
the right questions.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
Pharmaceutical Executive Daily: FDA Approves Fayuvi
3
The Battle to Own the GLP-1 Patient Journey
4
FDA Approves Kerendia for Adults with Chronic Kidney Disease and Type 1 Diabetes
5